Literature DB >> 22399227

Sp1 regulates human huntingtin gene expression.

Ruitao Wang1, Yawen Luo, Philip T T Ly, Fang Cai, Weihui Zhou, Haiyan Zou, Weihong Song.   

Abstract

Huntington's disease (HD) is a hereditary neurodegenerative disorder resulting from the expansion of a polyglutamine tract in the huntingtin protein. The expansion of cytosine-adenine-guanine repeats results in neuronal loss in the striatum and cortex. Mutant huntingtin (HTT) may cause toxicity via a range of different mechanisms. Recent studies indicate that impairment of wild-type HTT function may also contribute to HD pathogenesis. However, the mechanisms regulating HTT expression have not been well defined. In this study, we cloned 1,795 bp of the 5' flanking region of the human huntingtin gene (htt) and identified a 106-bp fragment containing the transcription start site as the minimal region necessary for promoter activity. Sequence analysis reveals several putative regulatory elements including Sp1, NF-κB, HIF, CREB, NRSF, P53, YY1, AP1, and STAT in the huntingtin promoter. We found functional Sp1 response elements in the huntingtin promoter region. The expression of Sp1 enhanced huntingtin gene transcription and the inhibition of Sp1-mediated transcriptional activation reduced huntingtin gene expression. These results suggest that Sp1 plays an important role in the regulation of the human huntingtin gene expression at the mRNA and protein levels. Our study suggests that the dysregulation of Sp1-mediated huntingtin transcription, combining with mutant huntingtin's detrimental effect on other Sp1-mediated downstream gene function, may contribute to the pathogenesis of HD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22399227     DOI: 10.1007/s12031-012-9739-z

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  65 in total

1.  Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity.

Authors:  F C Nucifora ; M Sasaki; M F Peters; H Huang; J K Cooper; M Yamada; H Takahashi; S Tsuji; J Troncoso; V L Dawson; T M Dawson; C A Ross
Journal:  Science       Date:  2001-03-23       Impact factor: 47.728

2.  Direct interaction between Sp1 and the BPV enhancer E2 protein mediates synergistic activation of transcription.

Authors:  R Li; J D Knight; S P Jackson; R Tjian; M R Botchan
Journal:  Cell       Date:  1991-05-03       Impact factor: 41.582

3.  Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95.

Authors:  Y Sun; A Savanenin; P H Reddy; Y F Liu
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

4.  Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.

Authors:  Haibing Jiang; Michelle A Poirier; Yideng Liang; Zhong Pei; Charlotte E Weiskittel; Wanli W Smith; Donald B DeFranco; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2006-09       Impact factor: 5.996

5.  Huntingtin inhibits caspase-3 activation.

Authors:  Yu Zhang; Blair R Leavitt; Jeremy M van Raamsdonk; Ioannis Dragatsis; Dan Goldowitz; Marcy E MacDonald; Michael R Hayden; Robert M Friedlander
Journal:  EMBO J       Date:  2006-11-23       Impact factor: 11.598

6.  Neogenesis of beta-cells in adult BETA2/NeuroD-deficient mice.

Authors:  Hsiang-po Huang; Khoi Chu; Eric Nemoz-Gaillard; Dorit Elberg; Ming-Jer Tsai
Journal:  Mol Endocrinol       Date:  2002-03

7.  Interaction of Huntington disease protein with transcriptional activator Sp1.

Authors:  Shi-Hua Li; Anna L Cheng; Hui Zhou; Suzanne Lam; Manjula Rao; He Li; Xiao-Jiang Li
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

8.  Transcriptional Regulation of TMP21 by NFAT.

Authors:  Shengchun Liu; Si Zhang; Kelley Bromley-Brits; Fang Cai; Weihui Zhou; Kun Xia; Jill Mittelholtz; Weihong Song
Journal:  Mol Neurodegener       Date:  2011-03-07       Impact factor: 14.195

9.  Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.

Authors:  H Li; S H Li; Z X Yu; P Shelbourne; X J Li
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

10.  Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models.

Authors:  Hong Qing; Guiqiong He; Philip T T Ly; Christopher J Fox; Matthias Staufenbiel; Fang Cai; Zhuohua Zhang; Shengcai Wei; Xiulian Sun; Chia-Hsiung Chen; Weihui Zhou; Ke Wang; Weihong Song
Journal:  J Exp Med       Date:  2008-10-27       Impact factor: 14.307

View more
  11 in total

1.  Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.

Authors:  Cesar L Moreno; Michelle E Ehrlich; Charles V Mobbs
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

2.  A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease.

Authors:  Kristina Bečanović; Anne Nørremølle; Scott J Neal; Chris Kay; Jennifer A Collins; David Arenillas; Tobias Lilja; Giulia Gaudenzi; Shiana Manoharan; Crystal N Doty; Jessalyn Beck; Nayana Lahiri; Elodie Portales-Casamar; Simon C Warby; Colúm Connolly; Rebecca A G De Souza; Sarah J Tabrizi; Ola Hermanson; Douglas R Langbehn; Michael R Hayden; Wyeth W Wasserman; Blair R Leavitt
Journal:  Nat Neurosci       Date:  2015-05-04       Impact factor: 24.884

Review 3.  Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis.

Authors:  Amit Kumar; Manisha Vaish; Rajiv R Ratan
Journal:  Drug Discov Today       Date:  2014-03-21       Impact factor: 7.851

4.  A Perspective on the Role of microRNA-128 Regulation in Mental and Behavioral Disorders.

Authors:  Ai-Sze Ching; Azlina Ahmad-Annuar
Journal:  Front Cell Neurosci       Date:  2015-12-14       Impact factor: 5.505

Review 5.  Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.

Authors:  Chunchen Xiang; Shun Zhang; Xiaoyu Dong; Shuang Ma; Shuyan Cong
Journal:  Front Mol Neurosci       Date:  2018-05-15       Impact factor: 5.639

6.  Disruption of zinc transporter ZnT3 transcriptional activity and synaptic vesicular zinc in the brain of Huntington's disease transgenic mouse.

Authors:  Li Niu; Li Li; Shiming Yang; Weixi Wang; Cuifang Ye; He Li
Journal:  Cell Biosci       Date:  2020-09-11       Impact factor: 7.133

7.  The specificity protein factor Sp1 mediates transcriptional regulation of P2X7 receptors in the nervous system.

Authors:  Paula García-Huerta; Miguel Díaz-Hernandez; Esmerilda G Delicado; María Pimentel-Santillana; M Teresa Miras-Portugal; Rosa Gómez-Villafuertes
Journal:  J Biol Chem       Date:  2012-11-08       Impact factor: 5.157

8.  Regulation of LRRK2 promoter activity and gene expression by Sp1.

Authors:  Juelu Wang; Weihong Song
Journal:  Mol Brain       Date:  2016-03-22       Impact factor: 4.041

9.  Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models.

Authors:  Meng Yu; Yuhua Fu; Yijiang Liang; Haikun Song; Yao Yao; Peng Wu; Yuwei Yao; Yuyin Pan; Xue Wen; Lixiang Ma; Saiyin Hexige; Yu Ding; Shouqing Luo; Boxun Lu
Journal:  Cell Res       Date:  2017-10-13       Impact factor: 25.617

Review 10.  Transcriptional Regulation of the Huntingtin Gene.

Authors:  Sarah B Thomson; Blair R Leavitt
Journal:  J Huntingtons Dis       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.